{"created":"2023-06-19T10:42:52.589161+00:00","id":2917,"links":{},"metadata":{"_buckets":{"deposit":"0cf90518-611e-4ac3-9732-2d7f7b0d6e1a"},"_deposit":{"created_by":11,"id":"2917","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"2917"},"status":"published"},"_oai":{"id":"oai:shiga-med.repo.nii.ac.jp:00002917","sets":["10:37"]},"author_link":[],"item_6_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2015-08","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"4","bibliographicPageEnd":"358","bibliographicPageStart":"350","bibliographicVolumeNumber":"13","bibliographic_titles":[{"bibliographic_title":"Clinical Genitourinary Cancer","bibliographic_titleLang":"en"}]}]},"item_6_date_granted_70":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2015-09-09"}]},"item_6_degree_grantor_68":{"attribute_name":"学位授与機関","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"ja","subitem_degreegrantor_name":"滋賀医科大学"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"14202","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_6_degree_name_67":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士（医学）","subitem_degreename_language":"ja"}]},"item_6_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background:\nSunitinib has been approved for the treatment of metastatic renal cell carcinoma (RCC). Sunitinib pharmacokinetics shows a large interpatient variability. ","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Patients and methods:\nA retrospective, observational clinical study of 21 patients with RCC was performed. Sunitinib was administered for 4 weeks of a 6-week cycle for the first cycle. We evaluated the association of sunitinib-induced toxicities and clinical outcomes with the trough total sunitinib concentration in a steady state during the first cycle. ","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Results:\nThe median total sunitinib concentration was 91.8 ng/mL (range, 49.8-205 ng/mL). There was an association between total sunitinib concentration and the severity of thrombocytopenia, anorexia, and fatigue. Patients with ≥ 100 ng/mL total sunitinib (n = 8), compared with patients with < 100 ng/mL (n = 13), had a greater incidence of Grade ≥ 3 toxicities (6 patients [75.0%] vs. 3 patients [23.1%]). Patients with < 100 ng/mL total sunitinib had significantly longer time to treatment failure (TTF) and progression-free survival (PFS) time than patients with ≥ 100 ng/mL (median TTF, 590 vs. 71 days; P = .04; median PFS, 748 vs. 238 days; P = .02). ","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"Conclusion:\nResults of this study suggest that therapeutic drug monitoring of sunitinib could be useful for avoiding severe toxicities. Dose reduction might be needed, especially when the total sunitinib concentration is ≥ 100 ng/mL, to avoid unnecessary early discontinuation of treatment. ","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_6_description_42":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Thesis or Dissertation","subitem_description_type":"Other"}]},"item_6_description_69":{"attribute_name":"学位授与年度","attribute_value_mlt":[{"subitem_description":"平成27年度","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_6_dissertation_number_71":{"attribute_name":"学位授与番号","attribute_value_mlt":[{"subitem_dissertationnumber":"甲第736号"}]},"item_6_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Elsevier","subitem_publisher_language":"en"}]},"item_6_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"25701374","subitem_relation_type_select":"PMID"}}]},"item_6_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.1016/j.clgc.2015.01.007"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1016/j.clgc.2015.01.007","subitem_relation_type_select":"DOI"}}]},"item_6_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2015 Elsevier Inc. All rights reserved. "}]},"item_6_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1558-7673","subitem_source_identifier_type":"PISSN"}]},"item_6_version_type_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"NODA, Satoshi","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-02-17"}],"displaytype":"detail","filename":"Noda-sunitinib-CGC-2015.pdf","filesize":[{"value":"471.6 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"Noda-sunitinib-CGC-2015.pdf","objectType":"fulltext","url":"https://shiga-med.repo.nii.ac.jp/record/2917/files/Noda-sunitinib-CGC-2015.pdf"},"version_id":"7b54215f-6359-4da6-bebb-d9e7986f209e"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Individualized pharmacotherpy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Kidney cancer","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Pharmacokinetics","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Tolerability","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Tyrosine kinase inhibitor","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma.","subitem_title_language":"en"}]},"item_type_id":"6","owner":"11","path":["37"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2016-05-17"},"publish_date":"2016-05-17","publish_status":"0","recid":"2917","relation_version_is_last":true,"title":["Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma."],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-09-15T05:17:10.720326+00:00"}